OTCMKTS:ICOTF iCo Therapeutics (ICOTF) Stock Price, News & Analysis → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free ICOTF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.35▼$0.3650-Day Range$0.30▼$0.4252-Week Range$0.80▼$1.82Volume2,900 shsAverage Volume4,760 shsMarket Capitalization$3.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get iCo Therapeutics alerts: Email Address Ad True Market InsidersThe CHIPS Act MotherlodeIf you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this.Click here to see my #1 investment for 2024. About iCo Therapeutics Stock (OTCMKTS:ICOTF)Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Read More Ad True Market InsidersThe CHIPS Act MotherlodeIf you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this.Click here to see my #1 investment for 2024. ICOTF Stock News HeadlinesMay 10, 2023 | wsj.comICO Group Ltd.February 25, 2023 | marketwatch.comAntisense & RNAi Therapeutics Market 2023 Estimated to Perceive Exponential Growth till 2028February 19, 2023 | finance.yahoo.comWomen's health therapeutics market size to increase by USD 30.35 billion: North America to account for 37% of market growth - TechnavioFebruary 19, 2023 | seekingalpha.comJasper Therapeutics releases promising early-stage data on sickle cell disease treatmentOctober 10, 2022 | usnews.comConsumers to Ditch Cafes for Coffee at Home Amid Rising Prices, Says ICOAugust 16, 2022 | investing.comSatellos Bioscience Inc (MSCL)June 1, 2022 | seekingalpha.comSatellos Bioscience GAAP EPS of -C$0.06December 16, 2021 | finance.yahoo.comSatellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular DystrophiesDecember 15, 2021 | finance.yahoo.comSatellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16thDecember 9, 2021 | finance.yahoo.comICOTF: Targeting Stem Cells for Muscular Dystrophy TreatmentDecember 6, 2021 | finance.yahoo.comSatellos Bioscience Announces New Board AppointmentsDecember 2, 2021 | investing.comiCo Therapeutics Inc (MSCL)November 29, 2021 | finance.yahoo.comSatellos Bioscience Reports Third Quarter 2021 Financial Results and Operational HighlightsOctober 27, 2021 | finance.yahoo.comSatellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations ServicesAugust 5, 2021 | finance.yahoo.comiCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.See More Headlines Receive ICOTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:ICOTF CUSIPN/A CIKN/A Webwww.icotherapeutics.com Phone(905) 336-6128Fax604-602-9699EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,110,000.00 Net MarginsN/A Pretax Margin-4,148.78% Return on EquityN/A Return on Assets-288.85% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-5.00Miscellaneous Outstanding Shares9,054,000Free FloatN/AMarket Cap$3.17 million OptionableNot Optionable Beta2.03 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesFrank GleesonPresident & Chief Executive OfficerWarren WhiteheadChief Financial OfficerMichael RudnickiChief Scientific OfficerJ. Robert HallVice President-Finance & AdministrationKey CompetitorsLongeveronNASDAQ:LGVNCyclacel PharmaceuticalsNASDAQ:CYCCPhaseBio PharmaceuticalsNASDAQ:PHASAppili TherapeuticsOTCMKTS:APLIFPhio PharmaceuticalsNASDAQ:PHIOView All Competitors This page (OTCMKTS:ICOTF) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iCo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.